Gavilimomab
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Mouse |
| Target | CD147 |
| Identifiers | |
| CAS Number |
244096-20-6  |
| ATC code | None |
| ChemSpider | none |
 (what is this?) (verify) | |
Gavilimomab (also known as ABX-CBL) is a mouse monoclonal antibody intended for use as an immunosuppressive biologic treatment of glucocorticoid-resistant graft versus host disease. It binds to the antigen CD147.[1] Gavilimomab proved slightly less effective than standard antithymocyte globulin therapy.[2]
It was originally developed by Abgenix,[1] which was later acquired by Amgen.
References
- 1 2 findarticles.com: Sangstat to Provide Clinical Development Update At JP Morgan H&Q Conference in San Francisco
- ↑ Macmillan, ML; Couriel, D; Weisdorf, DJ; Schwab, G; Havrilla, N; Fleming, TR; Huang, S; Roskos, L; et al. (Mar 2007). "A phase 2/3 multicenter randomized clinical trial of ABX-CBL versus ATG as secondary therapy for steroid-resistant acute graft-versus-host disease". Blood 109 (6): 2657–62. doi:10.1182/blood-2006-08-013995. PMID 17110457.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||
This article is issued from Wikipedia - version of the Thursday, November 19, 2015. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.